Results 91 to 100 of about 216,339 (397)
Heterogeneity Landscape of Circulating Tumor Cells in Clinical Utility
Advanced Therapeutics, EarlyView.This study reports the heterogeneity spectrum of circulating tumor cells. The factors involved in the spectrum promote CTCs to overcome barriers in the metastatic cascade but impact the clinical outcome of cancer patients. In summary, the heterogeneities in association with CTCs ultimately reduce patient survival and facilitate increasing mortality of ...
Md Kowsar Alam +5 more
wiley +1 more source
Mass spectrometry in ocular drug research
Mass Spectrometry Reviews, EarlyView., 2023 Abstract Mass spectrometry (MS) has been proven as an excellent tool in ocular drug research allowing analyzes from small samples and low concentrations. This review begins with a short introduction to eye physiology and ocular pharmacokinetics and the relevance of advancing ophthalmic treatments.
Eva M. del Amo +6 more
wiley +1 more source
Case report: Bevacizumab-induced cerebrovascular events: a case series report and literature review
Frontiers in OncologyIn clinical use, bevacizumab has improved the overall survival (OS) and progression-free survival (PFS) of malignant solid tumors, and the safe use of bevacizumab has gradually become the mainstream direction of clinical, nursing and pharmaceutical ...
Ke Chen +8 more
doaj +1 more source
Future Oncology, 2020 Hepatocellular carcinoma recurs in 70-80% of cases following potentially curative resection or ablation and the immune component of the liver microenvironment plays a key role in recurrence.
S. Hack +9 more
semanticscholar +1 more source
Impact of chronic exposure to bevacizumab on EpCAM-based detection of circulating tumor cells [PDF]
, 2015 BACKGROUND: Circulating tumor cells (CTCs) are often undetected through the immunomagnetic epithelial cell adhesion molecule (EpCAM)-based CellSearch(®) System in breast and colorectal cancer (CRC) patients treated with bevacizumab (BEV), where low ...
GAZZANIGA, PAOLA +7 more
core +1 more source
Drug Delivery Technologies for the Treatment of Age‐Related Macular Degeneration
Advanced Science, EarlyView.There are multiple therapeutic agents available for the treatment of both dry age‐related macular degeneration (AMD) and wet AMD. It is essential to continue innovation by introducing new drug delivery technologies that can incorporate those along with patient compliance and the accessibility of the technology into the early stages of research and ...
J Jesus Rodriguez‐Cruz +4 more
wiley +1 more source
Cancer Medicine, 2019 Purpose Combination of biological therapy and chemotherapy improves the survival of patients with metastatic colorectal cancer (mCRC). However, the optimal biological therapy sequence remains unclear.
Hung‐Chih Hsu +7 more
doaj +1 more source
Physics and Imaging in Radiation Oncology, 2018 Stereotactic body radiotherapy (SBRT) and bevacizumab are used in the treatment of colorectal liver metastases. This study prospectively evaluated changes in perfusion of liver metastases in seven patients treated with both bevacizumab and SBRT ...
Jay S. Detsky +6 more
doaj +1 more source
Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer
Frontiers in Oncology, 2022 BackgroundBevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor and is used in combination with first-line chemotherapy in the treatment of metastatic colorectal cancer.
Seijong Kim +9 more
doaj +1 more source
Bevacizumab for Malignant Gliomas [PDF]
Archives of Neurology, 2010 Malignant gliomas are the most common and aggressive primary brain tumors in adults. Despite optimal treatment with surgery, radiotherapy, and temozolomide, tumor recurrences are frequent and patients with malignant gliomas continue to have poor prognoses.
Fabio M. Iwamoto, Howard A. Fine
openaire +3 more sources